For adults with moderate to severe ulcerative colitis (UC) in whom TNF blockers did not work well

RINVOQ

results

On this page:

RINVOQ results
Real patient before and after endoscopy images

RINVOQ results

Experience rapid symptom relief with RINVOQ

only 8 weeks after starting rinvoq, many people (~3 out of 10) achieved remission, & 7 out of 10 people experienced less frequent bowel movements, fewer bloody stools, and a visible improvement of the colon lining


The 8-week study results include the total population treated with RINVOQ in 2 induction studies; 74% achieved clinical response at 8 weeks. Clinical response was based on frequency of bowel movements, fewer bloody stools, and endoscopy results.
 

The 1-year study results represent patients who continued on RINVOQ treatment for an additional 52 weeks after achieving clinical response at 8 weeks.

Click on the tabs below to see proven RINVOQ results

Week 2
Week 8
1 Year

RAPID SYMPTOM RELIEF*

In Study 1 and Study 2 combined, 62% of people taking RINVOQ 45 mg (n=660) reported less frequent bowel movements and bloody stools compared to 27% of people taking placebo (n=328) at Week 2

SYMPTOM RELIEF

In Study 2, 75% of people taking RINVOQ 45 mg (n=341) experienced symptom relief compared to 25% of people taking placebo (n=174) at Week 8

SYMPTOM RELIEF

At week 8, ~73% of people taking RINVOQ 45 mg (n=319) in study 1 and 75% of people taking RINVOQ 45 mg (n=341) in study 2 experienced symptom relief, compared to 27% of people taking placebo in study 1 (n=154) and 25% of people taking placebo in study 2 (n=174)

‡Based on the frequency of bowel movements, the amount of bloody stools, and the visible appearance of the colon lining.

VISIBLE COLON
LINING REPAIR†

In Study 2, 44% of people taking RINVOQ 45 mg (n=341) experienced a visible improvement of the colon lining compared to 8% of people taking placebo (n=174) at Week 8

VISIBLE COLON
LINING REPAIR†

At week 8, 36% of people taking RINVOQ 45 mg (n=319) in study 1 and 44% of people taking RINVOQ 45 mg (n=341) in study 2 experienced a visible improvement of the colon lining, compared to 7% of people taking placebo in study 1 (n=154) and 8% of people taking placebo in study 2 (n=174)

†Areas that were visually assessed may not represent repair of the entire colon lining.

RINVOQ helped significantly reduce fatigue at 8 weeks

LASTING
STEROID-FREE REMISSION

In study 3, of those who achieved remission at week 8, 68% of people taking RINVOQ 30 mg (n=58) and 57% of people taking RINVOQ 15 mg (n=47) achieved steroid-free remission at one year, compared to 22% of people taking placebo (n=54)

VISIBLE COLON
LINING REPAIR†

In Study 3, 62% of people taking RINVOQ 30 mg (n=154) and 49% of people taking RINVOQ 15 mg (n=148) experienced a visible improvement of the colon lining at one year, compared to 15% of people taking placebo (n=149)

†Areas that were visually assessed may not represent repair of the entire colon lining.

UC REMISSION AT 1 YEAR:

42% of people taking RINVOQ 15 mg and 52% of people taking RINVOQ 30 mg achieved remission, compared to 12% of people taking placebo

Safety Considerations

RINVOQ may cause serious side effects, including:

  • Serious infections. RINVOQ can lower ability to fight infections. Serious infections, some fatal, occurred, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses.
  • Increased risk of death in people age 50+ with at least 1 heart disease risk factor.
  • Cancer and immune system problems. Increased risk of some cancers, including lymphoma and skin. Current or past smokers have higher risk for lymphoma and lung cancer.
  • Increased risk of major cardiovascular events such as heart attack, stroke, or death in people 50+ with at least 1 heart disease risk factor, especially in current or past smokers.
  • Blood clots, some fatal, in veins of the legs or lungs and arteries. This occurred more often in people 50+ with at least 1 heart disease risk factor.
  • Serious allergic reactions. Do not take if allergic to RINVOQ or its ingredients.
  • Tears in the stomach or intestines; changes in certain laboratory test results.

Learn more about these and the full Important Safety Information below.

Keep scrolling for real patient endoscopy images from RINVOQ clinical trials

PATIENT 1

Real clinical trial patient endoscopy images. Adult patient with moderate to severe UC received RINVOQ 45 mg (induction) and 30 mg (maintenance), once daily. RINVOQ is a prescription medicine used to treat adults with moderate to severe ulcerative colitis when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.

Patient 1’s colon before Rinvoq

Before RINVOQ

Patient 1’s colon after 8 weeks on Rinvoq

Week 8

Patient 1’s colon after 1 year on Rinvoq

1 Year

Patient achieved visible colon lining improvement at Week 8 and a visibly normal colon lining at 1 year. In clinical trials, many patients showed visible colon lining improvement at Week 8 with RINVOQ 45 mg, and some showed a visibly normal colon lining at 1 year with RINVOQ 30 mg.†

†Areas that were visually assessed may not represent repair of the entire colon lining.

Individual results may vary.

PATIENT 2

Real clinical trial patient endoscopy images. Adult patient with moderate to severe UC received RINVOQ 45 mg (induction) and 15 mg (maintenance), once daily. RINVOQ is a prescription medicine used to treat adults with moderate to severe ulcerative colitis when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.

Patient 2’s colon before Rinvoq

Before RINVOQ

Patient 2’s colon after 8 weeks on Rinvoq

Week 8

Patient 2’s colon after 1 year on Rinvoq

1 Year

Patient did not achieve visible colon lining repair at Week 8, but did achieve visible colon lining improvement at 1 year. In clinical trials, many patients showed visible colon lining improvement at 1 year with RINVOQ 15 mg compared to placebo.†

†Areas that were visually assessed may not represent repair of the entire colon lining.

Individual results may vary.

Your doctor will decide which maintenance dose (15 mg or 30 mg) is right for you.

Once-daily RINVOQ can help people with UC get:

Rapid relief from UC symptoms* in as early as 2 weeks

*Based on the frequency of bowel movements and the amount of bloody stools. 

No bowel urgency, no abdominal pain, and significantly reduced fatigue at 8 weeks

Steroid-free remission at 1 year

Visible colon lining repair† even at 1 year

†Areas that were visually assessed may not represent repair of the entire colon lining.

Understanding the possible side effects of RINVOQ

Consider the benefits and risks of taking RINVOQ to make an informed treatment choice with your gastroenterologist.

Learn more about side effects

See the science
behind RINVOQ

Learn how RINVOQ works.

Watch video

What do you want from
UC treatment?

Consider what’s important to you—including rapid symptom relief, steroid-free remission, and visible colon lining repair.

Explore treatment benefits

Make once-daily RINVOQ part of your routine.
Get the facts about Taking RINVOQ for UC >

Take charge: More topics for you

Frequently asked questions about RINVOQ

Get answers to some of the most commonly asked questions about RINVOQ.

See RINVOQ FAQs >

Meet real RINVOQ patients

Find out what patients have to say about their experience with UC and RINVOQ.

Explore patient stories >